HC Wainwright Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report released on Tuesday, Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Invivyd Stock Performance

Invivyd stock opened at $0.85 on Tuesday. Invivyd has a 12 month low of $0.84 and a 12 month high of $5.20. The business’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $2.16. The company has a market cap of $101.59 million, a price-to-earnings ratio of -0.46 and a beta of 0.66.

Hedge Funds Weigh In On Invivyd

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new position in Invivyd in the first quarter valued at approximately $56,000. Tidal Investments LLC purchased a new position in Invivyd in the first quarter valued at approximately $126,000. XTX Topco Ltd lifted its stake in Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares during the last quarter. Chase Investment Counsel Corp bought a new stake in Invivyd during the 1st quarter valued at $271,000. Finally, Cornercap Investment Counsel Inc. bought a new stake in Invivyd during the 2nd quarter valued at $86,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.